{"name":"GATT Technologies BV","slug":"gatt-technologies-bv","ticker":"","exchange":"","domain":"gatttechnologiesbv.com","description":"GATT Technologies BV is a specialized pharmaceutical company focused on the development and commercialization of innovative medical devices and drugs. The company's primary product, TachoSil, is a marketed fibrin sealant used in surgical procedures to control bleeding and promote tissue adhesion.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TachoSil","genericName":"TachoSil","slug":"tachosil","indication":"Hemostasis support in cardiovascular surgery","status":"marketed"}]}],"pipeline":[{"name":"TachoSil","genericName":"TachoSil","slug":"tachosil","phase":"marketed","mechanism":"TachoSil is a hemostatic agent that combines fibrin glue with collagen to promote rapid blood clotting and wound sealing.","indications":["Hemostasis support in cardiovascular surgery","Hemostasis support in general surgery","Hemostasis support in orthopedic surgery"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQM3FwX093X0Z2MWhpWFdGUDBGeFdEc2dXbkE2d2hTa2tZRXpCUUtfMDJPOG1vTWluUklGa202S2VqekRhaGZjODVVRDV0YnJfQnlJanY1T2IyOXZqWDk1TEVxWkNCU2JtYlBFY2lKcmViSE85WFFnd3B6UllEbXlWWjNFal9WTXhmNzdWTmNwV1VPNldJZU5jN1E0aVM2dno2N0hlaVNDVzZZV3djZEN4Y3RFSGNBN2d6cWtYS0UxOHE4QmEyelBzOTAxWkszMUV2N2psYVo2eXFfbnIxcmtiWjFJUDRUamtMOVZfVnB0b3Nva3liQzN5VXBSWHNPeS0xZjJvUDdpX3k4RTA0S2lNdkFpZF81dkdoTjBSMXlhVl9mOFJNU1d2T1ZSSTduUTky?oc=5","date":"2026-02-17","type":"pipeline","source":"GlobeNewswire","summary":"AMT Medical Appoints Geert van Gansewinkel as CEO to Lead - GlobeNewswire","headline":"AMT Medical Appoints Geert van Gansewinkel as CEO to Lead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOaWw1RjRyUElVMTFqUDF5RGNVcFgtcGhCTnBLb2QzU2N5QXVkTmMwSWJZakQwUlBlWW04TWo1cnp0YTNiT0hObWhST0NvNG9zd09Ob0NlNGNQSXZZYzhoUWZJRjlsWWZURFlocjNKYndEcU5xX0l2RkJUTHl5Tk5HT2F5SG1FWW94RHFoWG9MdC1HckxhMVQxVHVDYjFiRnlqelpkakNkV0JJc0RxbWVSVGJsWnBPNW5QUnQyanBtdGpoZWJYbUlDSGFrOWlVTTZiVnQ0VUNELU82U0x0Y1k1Ni1LX0gteDhV?oc=5","date":"2023-11-15","type":"pipeline","source":"PR Newswire","summary":"Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding - PR Newswire","headline":"Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOZUhDUlhrSDZFN09nMVFYc2oycnRKTGdYNWtvUTdSalBwQ3ZiVWRoZk16ZWRBUjBFeW1iaUFwVzRpYXJoMzBVSFN2Nk5hcHRtQnk5UkhfeGdaSUpGUmdYcGlCTEx0c0ZWbEd2TkhIdUVCeW9fbU55dmJBRHo5SVN3eGhpTXpma1IzcG5QT1RpT2RUaUVPdWN2MGJvWFZNRTVIbUVzQXhLSno1OTdWcE82b2Z3Y3BWd1E5ZmZIbEpYNmFUa0IzN05kRXhZNnpRaUJMTUU4SnBXb2lOVnVXYWoxZ3hUaW9JRG4weHlDVnRVb3RlMTNmWUJZbkEwY2ZXZXFUWFAxYWNaVG55ZkcwOE84Q3VnQzNSLVdsLTVmLVd4STc5Z1NhdzlFZUFSZTRFYzR4NFdiLXhR?oc=5","date":"2020-05-18","type":"pipeline","source":"PR Newswire","summary":"GATT Technologies Announces €10.5M Series B Funding, Appointment of New CEO, and Expansion of Supervisory Board to Lead Company Through Next Development Stage - PR Newswire","headline":"GATT Technologies Announces €10.5M Series B Funding, Appointment of New CEO, and Expansion of Supervisory Board to Lead ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}